White Paper: Utility and Application of the VeriKine-HS Human Interferon Beta Serum ELISA

Content:

  • Multiple Sclerosis and IFN-β
  • IFN-β and Pharmacokinetics (PK)
  • IFN-β as an Anti-tumor Immunotherapeutics
  • IFN-β and TLR therapeutics
  • VeriKine-HS Human Interferon Beta Serum ELISA performance

Abstract

Interferon Beta (IFN-β), has long been known to function as an inhibitor of viral replication as part of the body’s innate antiviral response. IFN-β is also widely used as a treatment for Multiple Sclerosis patients, either as a single agent or as part of a combinatorial approach. In addition, with the resurgence of interest in antitumor immunity as a promising treatment approach for several types of cancer, there has been renewed focus on applying IFN-β as a therapy due to the anti-tumor and immunomodulatory properties of the protein. Furthermore, ligation of Toll-Like Receptors (TLRs) leads to IFN-β production and, as novel TLR agonists and antagonists are being developed as therapeutics for several diseases, this warrants the monitoring of IFN-β as a downstream readout for compound effectiveness. A phenomenon often observed with cytokines is their ability to exert opposing effects in different contexts. Therefore, during clinical trials it is crucial to monitor IFN-β levels in order to ensure a desirable outcome is obtained.

 

(Click here to download)

Find your product of interest by searching for category, species, molecule and/or application.

Visit our blog to read about recent developments in the fields of interferon, cytokine and biomarker research!

Sign up for our mailing list to be kept up-to-date on the latest promotions, company and product news.

Go to top